As in gardening, experimentation in the field of stem cell biology involves a measure of faith. Once the dormant seeds are planted, one must wait in anticipation for nature to take its course. On those sad occasions when nothing grows, one must evaluate the nature of the seed and the quality of the soil, and simply try again using the lessons learned from previous attempts. In the case of hematopoietic stem cells (HSCs), the dormant seeds are not fully characterized. A variety of studies have suggested that while the major HSC population in the mouse can be isolated by phenotype, numerically minor subsets remain to be found. Why do minor subsets matter when the major HSC population is fully capable of promoting rapid and sustained engraftment at a clonal level? The quest for ever-more-primitive stem cells has its roots in historical observations of the spleen colony-forming unit (CFU-s), once thought to represent the HSC but now known to largely be the product of more differentiated progenitors. Perhaps the most primitive of marrow stem cells may even be capable of differentiation into nonhematopoietic lineages, such as endothelium or other tissues, in addition to committing to hematopoietic development.
One difficulty encountered in seeking the mother of all HSCs in the marrow is the question posed in the title of this essay. Since little is known of the biology of these cells, it is not obvious how one might use defined culture conditions to study them. Another difficulty is the challenge of isolating rare cell populations, especially since primitive stem cells that may contaminate any given cell preparation at a level too low to be directly detected may nonetheless be a major source of growth. These issues make the quest for ever-more-primitive stem cells a daunting task indeed, and one that requires rigorous clonal analysis in a model system amenable to manipulation.
In this issue of Blood, Klarmann and colleagues (page 3120) use several culture conditions to promote the growth of mouse bone marrow cells that lack expression of c-kit, a receptor tyrosine kinase expressed at high levels by the major HSC population in mice. Previous studies have shown that c-kit-negative (c-kit neg ) cells fail to form CFU-s, radioprotect mice that underwent transplantation, or produce colonies in culture. However, competitive transplants, in which radioprotection is provided independently of c-kit neg cells, showed the derivation of c-kit-positive (c-kit pos ) HSCs from transplanted c-kit neg cells. The new work extends these data by reproducing this result in a culture system. Although in some cases the conversion to c-kit pos was due to expansion of mast cells, in other cases c-kit neg cells cultured for 25 days were capable of reconstituting animals that underwent transplantation in a competitive repopulation assay. It is important to note that all cultures were initiated using 500 or more cells, suggesting either that the critical cell is a rare member of the total population or that cell-cell interactions not provided at a sufficient level by the feeder cells are important. It is also possible that the cultures can be further optimized to allow for clonal analysis of the cells responsible for initiating growth in the cultures. As in the garden, progress in the laboratory is slow but ultimately rewarding.
-Gerald J. Spangrude

University of Utah
Thrombin paradox redux
Severe sepsis is both common and deadly. The pathophysiology of sepsis is complex and includes a nonlinear interplay between multiple cell types and soluble mediators. 1,2 Over the past decade, enormous resources have been expended on sepsis trials, with more than 10 000 patients enrolled in more than 20 placebo-controlled, randomized phase 3 clinical trials. The vast majority of these therapies have failed to improve survival in patients with severe sepsis. A notable exception is activated protein C, which was shown in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study to reduce 28-day all-cause mortality in this patient population. 3 The biologic plausibility of the PROWESS results is mired in a maze of inflammatory and coagulation pathways. Intensivists and hematologists (not to mention investigators from many other disciplines) have found themselves in an unlikely partnership, struggling to get their arms around the problem. If any consensus has been reached, it goes something like this: (1) activation of both inflammation and coagulation contributes to the pathophysiology of severe sepsis and organ dysfunction, (2) therapies that target only the inflammatory cascade (eg, antimediator therapy) or only the coagulation pathway (eg, antithrombin agents) do not improve survival, and (3) therapies that target both inflammatory and coagulation pathways (eg, activated protein C) hold more promise.
Just as the dust is settling, a study by Kerlin and colleagues (page 3085) promises to kick up another storm. This study provides evidence that factor V (FV) Leiden confers a survival advantage in severe sepsis and in an animal model of endotoxemia. While the numbers of patients in the PROWESS trial with the FV Leiden mutation were relatively small, the inclusion of the animal data goes a long way 3077 BLOOD, 1 NOVEMBER 2003 ⅐ VOLUME 102, NUMBER 9
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From toward supporting their conclusion. Although much more work will be required to elucidate the mechanism(s) by which FV Leiden protects against sepsis mortality, the results amount to a fascinating paradigm shift, summarized as follows: (1) thrombin generation may be protective in the setting of sepsis, (2) the effect of thrombin is dose-dependent-a little more thrombin (FV carrier) is good, while too much thrombin (FV homozygous) is not-and (3) the FV Leiden mutation may have evolved as a means of protecting not so much against the saber-toothed tiger, but rather as a defensive weapon in the host-pathogen arms race.
If these results hold true in large populations of patients with severe sepsis, and if the mechanism is one of increased thrombin generation (and perhaps secondary activation of endogenous protein C), then we will be forced to revise our model of sepsis pathophysiology yet again, this time assigning a protective role to the coagulation pathway (at least up to a certain level of activation). Does that mean we are back to a simplified version of sepsis pathogenesis in which one or another component of the inflammatory cascade is the "Darth Vader" of the host response? The answer is most certainly no. As with most, if not all, biologic systems, the sepsis network is likely to display small-world properties consisting of diverse nodes, hubs, links, and connection weights. Mapping the topology of the network will keep us busy well into the millennium. That said, the revised model in its present form raises interesting therapeutic questions. For example, would a re-engineered activated protein C molecule that lacks anti-Va and antiVIIIa function yet retains nonanticoagulant activity yield an improved therapeutic window? Moreover, could one actually titrate the systemic infusion of a prothrombotic agent such as rVIIa to optimize thrombin generation while minimizing the deleterious effects of tissue factor/VIIa/activated factor X-mediated cell activation? Given the unpredictable turns in this field, I would not be surprised if the answer is yes on both counts. 
TPO: tapping into the HOX clock
The 39 members of the HOX homeobox gene family are organized in 4 paralogous clusters of 8 to 11 genes. HOX genes encode DNA-binding proteins that are deployed in overlapping domains along various body axes during embryonic development. This sequential activation of HOX genes in time and space, the "HOX clock" if you will, generally proceeds in a 3Ј to 5Ј direction within a given cluster and is critical for the proper positioning of structures along those axes, which include the vertebrae, the limbs, and the gastrointestinal and genitourinary tracts. Kirito and colleagues (page 3172) report that thrombopoietin (TPO) increases HOXB4 expression in hematopoietic cell lines and, conversely, that TPO-deficient primitive marrow cells have reduced HOXB4 levels. They provide evidence that TPO activates HOXB4 via a p38-dependent pathway involving the upstream stimulating factor 1 (USF-1) transcription factor. These data suggest that the effects of TPO on stem cell expansion are mediated in part by HOXB4. The TPO-induced up-regulation of HOXB4 in cell lines is modest-only 2-to 3-fold; however, this magnitude of up-regulation was shown by other investigators, using retroviral vectors to increase HOXB4 expression, to be sufficient to expand stem cells. These findings must be qualified by the fact that the magnitude of the stem cell defect in TPO-deficient mice is much greater than in HOXB4-deficient animals, suggesting that TPO's salutary effects on stem cells involve other downstream targets, perhaps including other HOX family members. Although Kirito et al show that TPO does not up-regulate the HOXA9 gene, it is possible that it activates other HOXB4 paralogs, such as HOXA4 and HOXC4.
It is difficult to reconcile how HOX genes play a role in such disparate activities as limb development and hematopoiesis. One speculation is that HOX proteins function as timers or sequencers for complex differentiation processes. In this model, different developmental programs use the HOX clock to order maturational events specific for that tissue. In one study, the GATA-1 transcription factor was shown to regulate the HOXB2 gene in erythroid cell lines, suggesting another pathway by which HOX genes could be activated in blood cells. It seems likely that other hematopoietic cytokines that influence stem cell proliferation also regulate HOX gene expression. Does the hematopoietic system have an axis? Only a more careful delineation of HOX protein expression in marrow cells will answer that question.
-H. Jeffrey Lawrence
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